Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl E Clarke

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
The Lancet. Neurology|July 21, 2004
Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's diseaseCarl E Clarke
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2004
A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?Carl E Clarke
Lancet (London, England)|March 16, 2005
Rasagiline for motor complications in Parkinson's diseaseCarl E Clarke
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?Carl E Clarke
BMJ (Clinical Research Ed.)|September 20, 2015
Initial drug treatment in Parkinson's diseaseSharon Muzerengi, Carl E Clarke
BMJ (Clinical Research Ed.)|November 5, 2015
Authors' reply to Braithwaite and ElringtonSharon Muzerengi, Carl E Clarke
American Family Physician|April 13, 2007
Parkinson's diseaseCarl E Clarke, A Peter Moore
The Lancet. Neurology|April 25, 2006
Idiopathic intracranial hypertensionAlex K Ball, Carl E Clarke
BMJ Clinical Evidence|May 21, 2009
Parkinson's diseaseCarl E Clarke, A Peter Moore
JAMA Neurology|June 27, 2022
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-ReplyRichard Gray, Crispin Jenkinson, Carl E Clarke
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
The Lancet. Neurology|July 21, 2004
Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's diseaseCarl E Clarke
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2004
A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?Carl E Clarke
Lancet (London, England)|March 16, 2005
Rasagiline for motor complications in Parkinson's diseaseCarl E Clarke
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?Carl E Clarke
BMJ (Clinical Research Ed.)|September 20, 2015
Initial drug treatment in Parkinson's diseaseSharon Muzerengi, Carl E Clarke
BMJ (Clinical Research Ed.)|November 5, 2015
Authors' reply to Braithwaite and ElringtonSharon Muzerengi, Carl E Clarke
American Family Physician|April 13, 2007
Parkinson's diseaseCarl E Clarke, A Peter Moore
The Lancet. Neurology|April 25, 2006
Idiopathic intracranial hypertensionAlex K Ball, Carl E Clarke
BMJ Clinical Evidence|May 21, 2009
Parkinson's diseaseCarl E Clarke, A Peter Moore
JAMA Neurology|June 27, 2022
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-ReplyRichard Gray, Crispin Jenkinson, Carl E Clarke
Pageof 8